Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...

Results from a phase 3 clinical trial, recently published in The Lancet Oncology, present a significant breakthrough in the field of prostate cancer surgery. The NeuroSAFE technique, a novel approach ...

Testosterone testing and treatment have increased significantly over the past 2 decades, yet clinical practices remain inconsistent. 1,2 Despite rising awareness and prescription trends, up to 25% of ...

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

In some people with kidney stones, low-intensity shockwave therapy (LIST) breaks them up. And in some with heart disease and fractures, LIST coaxes the body to produce new blood vessels that help with ...

No significant association found between phosphodiesterase type 5 inhibitor use and biochemical recurrence after radical treatment. Oral drugs to treat erectile dysfunction after radical treatment for ...